» Articles » PMID: 39841684

Administration of Antigenically Distinct Influenza Viral Particle Combinations As an Influenza Vaccine Strategy

Overview
Journal PLoS Pathog
Date 2025 Jan 22
PMID 39841684
Authors
Affiliations
Soon will be listed here.
Abstract

One approach for developing a more universal influenza vaccine is to elicit strong immune responses against canonically immunosubdominant epitopes in the surface exposed viral glycoproteins. While standard vaccines typically induce responses directed primarily against mutable epitopes in the hemagglutinin (HA) head domain, there are generally limited or variable responses directed against epitopes in the relatively more conserved HA stalk domain and neuraminidase (NA) proteins. Here we describe a vaccine approach that utilizes a combination of wildtype (WT) influenza virus particles along with virus particles engineered to display a trimerized HA stalk in place of the full-length HA protein to elicit both responses simultaneously. After initially generating the "headless" HA-containing viral particles in the A/Hawaii/70/2019 (HI/19) genetic background and demonstrating the ability to elicit protective immune responses directed against the HA-stalk and NA, we co-formulated those virions with unmodified WT viral particles. The combination vaccine elicited "hybrid" and protective responses directed against the HA-head, HA-stalk, and NA proteins in both naïve and pre-immune mice and ferrets. Collectively, our results highlight a potentially generalizable method combining viral particles with differential antigenic compositions to elicit broader immune responses that may lead to more durable protection from influenza disease post-vaccination.

References
1.
Broecker F, Liu S, Suntronwong N, Sun W, Bailey M, Nachbagauer R . A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains. NPJ Vaccines. 2019; 4:31. PMC: 6642189. DOI: 10.1038/s41541-019-0126-4. View

2.
Walz L, Kays S, Zimmer G, von Messling V . Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype. J Virol. 2018; 92(17). PMC: 6096819. DOI: 10.1128/JVI.01006-18. View

3.
Skarlupka A, Bebin-Blackwell A, Sumner S, Ross T . Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains. J Virol. 2021; 95(17):e0075921. PMC: 8354223. DOI: 10.1128/JVI.00759-21. View

4.
Bailey M, Duehr J, Dulin H, Broecker F, Brown J, Arumemi F . Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model. Nat Commun. 2018; 9(1):4560. PMC: 6212565. DOI: 10.1038/s41467-018-07008-0. View

5.
Paget J, Spreeuwenberg P, Charu V, Taylor R, Iuliano A, Bresee J . Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project. J Glob Health. 2019; 9(2):020421. PMC: 6815659. DOI: 10.7189/jogh.09.020421. View